Navigation Links
European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference

t of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM is a trademarks of MediGene AG

- ends -

MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. A second drug has been approved by the FDA. A third drug was recently inlicensed to market this drug in Europe. In addition, several drug candidates are currently in clinical development. MediGene also possesses innovative platform technologies.

Contact MediGene AG: Email:

investor@medigene.com

Fax: ++49 - 89 - 85 65 - 2920 Julia Hofmann/Dr. Georg Dönges, Public Relations Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim, Investor Relations Tel.: ++49 - 89 - 85 65 - 2946



'"/>




Page: 1 2

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
5. Malvern initiates European user group meetings for chemical imaging
6. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. Inspire Announces Presentations at Two European Scientific Conferences
10. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
11. Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress

Post Your Comments:
(Date:12/4/2009)...c. 4 Suneva Medical, a privately-h...ced the appointment of Philip Ranker as Vice Presi...r. Ranker will lead all Suneva Medical,s general a...ounting, IT, IR, administration and human resource...agement team. ,, "One of my key objectives as ...
(Date:12/4/2009)... Drs. Neal Shore and E. David Crawf...n (PSA) recurrence from the additional analysis of...te in a Phase III pivotal study of FIRMAGON® ...olide in prostate cancer patients during the first...received FIRMAGON 240/80 mg/month had a recurrence...
(Date:12/3/2009)... Allen Medical Systems, ...RC ), today announced the launch of its new Allen ...business website www.AllenAmatech.com . ,, ... identity and includes an online version of the ne...design specifications for the products. "We hope t...
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 1Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 2Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 3AMDL CEO Featured in CEOCFO Magazine 3B Details Progress on DR 70 International Commercialization Strategy 26 Confidence in FY2009 Financial Forecast 49211 1AMDL CEO Featured in CEOCFO Magazine 3B Details Progress on DR 70 International Commercialization Strategy 26 Confidence in FY2009 Financial Forecast 49211 2AMDL CEO Featured in CEOCFO Magazine 3B Details Progress on DR 70 International Commercialization Strategy 26 Confidence in FY2009 Financial Forecast 49211 3Hartford grants increase support for geriatric social work training 49209 1Hartford grants increase support for geriatric social work training 49209 2Hartford grants increase support for geriatric social work training 49209 3
...ne in the Treatment of Patients with Relapsed/Ref...ented Tomorrow, Tuesday, June 3rd at 12:0...rmaceuticals,Inc. (Nasdaq: KERX ) today announced...ave been selected for both poster presentation and...al Oncology Meeting,currently taking place in Chic...
...erican Society of Clinical Oncology (ASCO),annual ...vival vs. external c...c.,(Nasdaq: IDMI ) today announced follow-up resu...t the product candidate was well tolerated, induce...sponses, and showed a,positive survival trend in H...
Other Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 2Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 3Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 4Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 5IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients 2IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients 3IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients 4
(Date:12/4/2009)...earchers, from the School of Medicine,s Department...ys by which products of lipid peroxidation and som...abolized. The pathways were identified by a combin.... The findings shed new light on the mechanism of ... also known as "the date rape drug." The manuscrip...
(Date:12/4/2009)...immediately or 3 weeks later, study shows , ... surgical repair or reconstruction of multiple-lig..., a new study has found. , Multiple-ligament kn...s that can occur in high-impact car crashes or in ...y to repair these injuries hasn,t been definitivel...
(Date:12/4/2009)...s Historic Effort but Points out Potential Risk if...ealth Care Reform ,, NEW YORK, Dec. 4 /PRNews...edicine today published a Perspective opinion pi...Irwin Redlener, M.D., president, Children,s Health...reparedness and Professor of Clinical Population &...
(Date:12/4/2009)...ookah, research shows , , FRIDAY, Dec. 4... cigarettes for smoking tobacco, researchers say. ...co with a water pipe inhale carbon monoxide and ni...and nicotine addiction. , The study included 31...ng a water pipe and a single cigarette. After each...
(Date:12/4/2009)...PRNewswire-FirstCall/ -- When the spread of H1N1 f... of Health Services needed to get more information...n Sonic Foundry, Inc. (Nasdaq: SOFO ), the reco... knowledge management, for a live webinar in which...h Services, will share how in-house webcasting rel...
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:Water Pipes No Safer Than Cigarettes 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3
...o be the most powerful indicator of heart disease....reased levels of total amount cholesterol in blood...tein)or 'bad' cholesterol and HDL(High-Density Lip...d molecule called// apolipoprotein, which they bel...
...s the world over, with India being touted as the "...erious diseases that diabetics can be affected wit...the deterioration of nerves in the body. A diabeti...abetes will develop// neuropathy. A study by ...
...uing the field of medicine and patients are now de... medical error happens. However, doctors are often...ey do not care. In fact, doctors confessed to bein...ng patients, doctors, and// patients and doctors t...
...eceived a patient, a two-month-old baby with white...are disease caused due to a deficiency of lipoprot... 10 million children. Doctors said that the baby w...his condition could be either due to// ‘familial l...
...a common genetic mutation called C150T transition ...scovering a "fountain of youth". This genetic muta...lood cells, in a study of a group of 52 Italian ce...he age// of 99. Mitochondria are so-called "o...
...ersity of Rochester, New York suggests that the ac...mmatory and anti-coagulant properties,which until ...also help reduce the damage caused by stroke. Rese...ng apoptosis, a form of programmed cell death. The...
Other Medicine News:
Disposable Lacrimal Dilators
Reusable Double Dilators
Skin Tone External Eyelid Weights
Contour Design Eyelid Implants (Gold)
Medicine Products: